

Rhode Island Medical Assistance Prior Authorization Program

RHODE ISLAND MEDICAL ASSISTANCE PROGRAM DEPARTMENT OF HUMAN SERVICES ENHANCED PRIOR AUTHORIZATION PROGRAM

Use Web	Drugs covered under Prior	Relevant Diagnosis / Physical Status	Approval Criteria or Documentation required
PA	Authorization		
Form			
PA09	Вотох	SPASTICITY	EVIDENCE OF RELEVANT DIAGNOSIS
		Narcolepsy Depressive Disorder	
PA02	CNS STIMULATORS	Major Depressive Disorder Major Depressive Affective Disorder ADD-Attention Deficit Disorder	EVIDENCE OF RELEVANT DIAGNOSIS
		ADHD-Attention Deficit Hyperactivity Disorder	
PA05	FOLLICLE STIMULATING HORMONE	Hypogonadism	MALES ONLY EVIDENCE OF RELEVANT DIAGNOSIS
PA11	FUZEON	HIV	APPROVAL LIMITED TO INFECTIOUS DISEASE SPECIALISTS PERSISTENT VEREMIA WITH CURRENT THERAPY CURRENTLY PRESCRIBED 3 ANTIRETROVIRALS FAILED > 6 DIFFERENT ANTIRETROVIRAL DRUG THERAPIES (EQUIVALENT TO TWO COURSES OF TREATMENT)
PA06	GROWTH HORMONES	GH DEFICIENCY — ADULT ONSET	APPROVAL LIMITED TO ENDOCRINOLOGISTS
		GHD AS A RESULT OF INJURY	DIAGNOSTIC TEST RESULTS:
		PREVIOUS CHILDHOOD GROWTH HORMONE DEFICIENCIES REQUIRING CONTINUOUS	Insulin tolerance test with growth hormone (GH) levels < 5ng/ml or Arginine stimulation test with GH levels < 5ng/ml (or < 9ng if arginine combined with GH-releasing hormone or
		TREATMENT INTO ADULTHOOD	An equivalent diagnosis test
PA01	MODAFINAL	NARCOLEPSY DEPRESSION PARKINSONISM CENTRAL SLEEP APNEA MS INDUCED FATIGUE	Evidence of relevant diagnosis
PA10	Agents Treating	PRIMARY PULMONARY HYPERTENSION	APPROVAL LIMITED TO CARDIOLOGISTS AND PULMONOLOGISTS
	Pulmonary Hypertension	SECONDARY PULMONARY HYPERTENSION WITH A CONNECTIVE TISSUE DISORDER	FUNCTIONAL WHO CLASS OF I, II, III, OR IV
PA04	WEIGHT LOSS / ANTI-OBESITY	BMI > 30kg/m ² or	INITIAL COVERAGE:
		•	Patient meets approval criteria. Approval will be for 3 months.
		BMI 27-30 kg/m² And 2 risk factors Diabetes Mellitus Hypertension Hyperlipidemia	MONTH 3-6 COVERAGE:
			Patient has weight lost of 4 lbs by first month and maintained or exceed this loss in month 2 and 3. Approval will be for additional 3 months.
			MONTH 7-12 COVERAGE:
			Patient weighs less than or equal to the weight at the 3-month time period. Approval will be for an additional 6 months.
			MONTHS BEYOND 12 MONTHS:
			Requires 6 months break in therapy after which initial criteria begins
PA12	XOLAIR	Аѕтнма	APPROVAL LIMITED TO PULMONOLOGISTS, ALLERGISTS, AND IMMUNOLOGISTS AEROALLERGEN PRESENCE IGE > 30 IU/ML INADEQUATELY CONTROLLED ASTHMA ON ORAL/INHALED MEDICATIONS
PA16	CHRONIC	CHRONIC IDIOPATHIC CONSTIPATION	HISTORY OF AT LEAST 2 CONSTIPATION ICD-9'S
	IDIOPATHIC CONSTIPATION	SSIZO 2023 ATTENDED	HISTORY OF AT LEAST 1 PRESCRIPTION LAXATIVE IN LAST 6 MONTHS ATTEMPT & FAILURE OF AT LEAST 2 DIFFERENT LAXATIVES

Rhode Island Medical Assistance Prior Authorization Program

Criteria and forms for submission of patient information for prior authorization approval are available at the DHS Medicaid Website: www.dhs.ri.gov/dhs/heacre/provsvcs/mpharpa.htm

CURRENT DRUGS REQUIRING PRIOR AUTHORIZATION AND PA REQUEST FORM.

PA01	Modafinal	
PA02	CNS Stimulators	
PA04	Weight Loss / Anti-Obesity Follicle Stimulating Hormone	
PA05		
PA06	Growth Hormones	
PA09	Botox	
PA10	Agents for Treating Pulmonary Hypertension	
PA11	. Fuzeon	
PA12	Xolair	
PA16	PA16 Chronic Idiopathic Constipation	